Advocates Push for Domestic U.S. Peptide Manufacturing Amid Regulatory Shifts
Venture capitalists from Haus Fund are advocating for the relocation of the peptide pharmaceutical supply chain to the United States. This movement aims to address concerns regarding the 'gray market' and sourcing uncertainties currently plaguing the industry. The push comes as a response to recent U.S. Department of Health and Human Services (HHS) interim policy decisions that allow certain unapproved peptides for compounding, a move criticized by FDA scientists for lacking safety and efficacy evidence. The debate highlights a tension between expanding access through telehealth and maintaining rigorous clinical trial standards. While companies like Hims & Hers are aligning with the domestic manufacturing narrative, industry experts warn that bypassing traditional approval processes could create a parallel, under-regulated market. Currently, much of the U.S. prescription active pharmaceutical ingredients (API) are sourced from India, the EU, and China.
Topics: biotechnology compounding pharmacy FDA regulation peptides pharmaceutical supply chain